Liu and colleagues discovered that Brivanib acts as a novel synergistic agent for cGAS, significantly enhancing the STING-TBK1-IFN-I response induced by cancer chemotherapy in vitro and in vivo(Liu et al., 2023a). This evidence concerns the gene STING1 and cancer.